{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:04Z","timestamp":1791849364685,"version":"4.3.4"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a cancer of bone marrow plasma cells. A noteworthy ensemble of therapies has been introduced over the past quarter century that exert antimyeloma activities through diverse mechanisms and achieve durable disease control in many patients. The discovery that proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) target specific plasma cell features that reflect disease biology and exert antimyeloma activity led to transformative changes in treatment algorithms. Recently, advances in immunotherapy have emerged and represent a promising option with the potential to capture immunologic memory and yield more durable responses in MM patients. Idecabtagene vicleucel and ciltacabtagene autoleucel are chimeric antigen receptor (CAR) T-cell immunotherapies that attach to the extracellular domain of the B-cell maturation antigen (BCMA) and have demonstrated significant response rates in heavily-treated patients. These agents are FDA-approved for relapsed and\/or refractory (RR)MM patients previously treated with PIs, IMiDs, and CD38-directed monoclonal antibodies. Most patients who receive CAR T-cell therapy relapse after prolonged or brief remission, and a more thorough understanding of the resistance mechanisms following CAR T-cell infusion is needed. Bispecific antibodies (BsAbs) are engineered to simultaneously bind to both cancer and immune cells and trigger a direct tumor-specific cytotoxic response. BsAbs and CAR T-cells are major histocompatibility complex (MHC)-independent approaches to treat MM and do not require T-cell receptor (TCR) specificity. Agents that target BCMA and G protein-coupled receptor class C group 5 member D (GPRC5D) demonstrate impressive clinical responses, while early-phase trials targeting FcRH5 are promising. Here, we provide a comprehensive overview of their individual efficacy, adverse effects, and limitations that impact broader application.<\/jats:p>","DOI":"10.3389\/fonc.2025.1578529","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:20:37Z","timestamp":1750418437000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure"],"prefix":"10.3389","volume":"15","author":[{"given":"Jeries","family":"Kort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuja","family":"Senigarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","article-title":"A roadmap towards improving outcomes in multiple myeloma","volume":"14","author":"Mohty","year":"2024","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"29","author":"Garfall","year":"2024","journal-title":"Annu Rev Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J\nClin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.CA","volume":"73","author":"Siegel","year":"2023","journal-title":"Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.2018.101.issue-2","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J haematology."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e54479","DOI":"10.7759\/cureus.54479","article-title":"Non-secretory multiple myeloma: A new observation and review of the literature","volume":"16","author":"Ouzzif","year":"2024","journal-title":"Cureus."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03984-w","article-title":"Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma","volume":"99","author":"Migkou","year":"2020","journal-title":"Ann Hematology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17219\/acem\/141455","article-title":"Non-secretory multiple myeloma: diagnosis and management","volume":"31","author":"Charli\u0144ski","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone Induction Followed by Lenalidomide and Dexamethasone Maintenance in Patients with Newly Diagnosed Myeloma without Intent for Immediate Autologous Stem Cell Transplant: Results of the Randomised Phase III SWOG","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/095952874402700129","article-title":"Remarks on the pathology of mollities ossium; with cases","volume":"27","author":"Solly","year":"1844","journal-title":"Med Chir Trans"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-540-85772-3_1","article-title":"History of multiple myeloma","volume":"183","author":"Kyle","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0140-6736(02)86528-X","article-title":"Papers on clinical pathology","volume":"50","author":"Bence Jones","year":"1847","journal-title":"Lancet"},{"key":"B24","first-page":"33","article-title":"Zur Symptomatologie des Multiplen Myeloms: Beobachtung von Albumosurie","volume":"14","author":"Kahler","year":"1889","journal-title":"Prague Med Wchnschr."},{"key":"B25","first-page":"37","article-title":"Immunological reactions of bence-jones proteins: I. Differences between bence-jones proteins and human serum proteins","volume":"33","author":"Bayne-Jones","year":"1922","journal-title":"Bull Johns Hopkins Hosp."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195603\/04)9:2<262::aid-cncr2820090210>3.0.co;2-b","article-title":"Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins","volume":"9","author":"Korngold","year":"1956","journal-title":"Cancer."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(47)90375-9","article-title":"Urethane and stilbamidine in multiple myeloma: report on two cases","volume":"2","author":"Alwall","year":"1947","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"B29","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806)","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V27.3.328.328","article-title":"A controlled trial of urethane treatment in multiple myeloma","volume":"27","author":"Holland","year":"1966","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V30.1.74.74","article-title":"Melphalan in multiple myeloma","volume":"30","author":"Hoogstraten","year":"1967","journal-title":"Blood."},{"key":"B32","article-title":"A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma","volume":"16","author":"Maas","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"B33","article-title":"Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma","volume":"51","author":"Salmon","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.208.9.1680","article-title":"Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-014233:2<533::aid-cncr2820330231>3.0.co;2-z","article-title":"Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU","volume":"33","author":"Lee","year":"1974","journal-title":"Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","article-title":"Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol","volume":"63","author":"Case","year":"1977","journal-title":"Am J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.04.005","article-title":"The proteasome in terminal plasma cell differentiation","volume":"49","author":"Cenci","year":"2012","journal-title":"Semin Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082117","article-title":"Targeting multiple myeloma through the biology of long-lived plasma cells","volume":"12","author":"Utley","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.925804","article-title":"Targeting proteasomes in cancer and infectious disease: A parallel strategy to treat Malignancies and microbes","volume":"12","author":"Ignatz-Hoover","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.23","article-title":"Therapeutics to harness the immune microenvironment in multiple myeloma","volume":"5","author":"Ignatz-Hoover","year":"2022","journal-title":"Cancer. Drug Resist"},{"key":"B42","article-title":"New contributions in sterol metabolism","volume":"74","author":"Schoenheimer","year":"1931","journal-title":"Sci 1928; New Series."},{"key":"B43","article-title":"The nobel prize in chemistry 2004","volume-title":"NobelPrize.org. Nobel prize outreach AB 2024","year":""},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)34041-4","article-title":"The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins","volume":"286","author":"Driscoll","year":"1990","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.20.7751","article-title":"ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin","volume":"86","author":"Eytan","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033985","article-title":"The proteasome and its network: engineering for adaptability","volume":"12","author":"Finley","year":"2020","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.3.787","article-title":"Skeletal muscle proteasome can degrade proteins in an ATP-dependent process that does not require ubiquitin","volume":"86","author":"Driscoll","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.11.4986","article-title":"An ATP-stabilized inhibitor of the proteasome is a component of the 1500-kDa ubiquitin conjugate-degrading complex","volume":"89","author":"Driscoll","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky lecture: Bench-to-Bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.672","article-title":"Real-world evidence for autologous stem cell transplantation in elderly multiple myeloma patients","volume":"31","author":"Kort","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.024","article-title":"Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life","volume":"28","author":"Joseph","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B54","article-title":"Emerging strategies to manage relapsed and\/or refractory Multiple Myeloma","volume":"37","author":"Driscoll","year":"2023","journal-title":"Oncol (Williston Park NY)."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019637","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705228","article-title":"Biochemical and structural analysis of the interaction between \u03b2-amyloid and fibrinogen","volume":"128","author":"Zamolodchikov","year":"2016","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"JCO"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with accepta ble toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2016.52.10.2543308","article-title":"Daratumumab: monoclonal antibody therapy to treat multiple myeloma","volume":"52","author":"Xia","year":"2016","journal-title":"Drugs Today (Barc)."},{"key":"B63","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA review of daratumumab for the treatment of adult patients with multiple myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunology Immunother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2018-99-117209","article-title":"Efficacy and toxicity profile of elotuzumab for multiple myeloma: A systematic review and meta-analysis","volume":"132","author":"Jamil","year":"2018","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1056\/NEJMoa1607751","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leukemia lymphoma."},{"key":"B73","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/hematolrep16040058","article-title":"The real-world outcomes of relapsed\/refractory multiple myeloma treated with elotuzumab, pomalidomide, and dexamethasone","volume":"16","author":"Nakayama","year":"2024","journal-title":"Hematol Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050415","article-title":"Tumor-specific T-bodies: towards clinical application","volume":"45","author":"Eshhar","year":"1997","journal-title":"Cancer Immunology Immunother"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood J Am Soc Hematology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Trans Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1200\/JCO.2023.41.16_suppl.8049","article-title":"Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies","volume":"41","author":"Firestone","year":"2023","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2406799","article-title":"A belantamab mafodotin revival in multiple myeloma therapy","volume":"391","author":"Trudel","year":"2024","journal-title":". N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.20517\/cdr.2024.39","article-title":"Unraveling the complexity of drug resistance mechanisms to T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review","volume":"7","author":"Sch\u00fctt","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052\u2013101 Part 1","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood J Am Soc Hematology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000434","article-title":"Firestone, Sham Mailankody; Current use of CAR T cells to treat multiple myeloma","volume":"1","author":"Ross","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B\u2013lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood J Am Soc Hematology."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134319","article-title":"Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa Study","volume":"136","author":"Raje","year":"2020","journal-title":"Blood."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1182\/blood-2023-182141","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2\u20134 prior lines of therapy using a matching-adjusted indirect comparison","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"B99","article-title":"US Food and Drug Administration approves Bristol Myers Squibb\u2019s and bluebird bio\u2019s Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma","volume-title":"News release. Bristol Myers Squibb and Bluebird Bio","year":""},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022","article-title":"KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood."},{"key":"B101","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2022.40.16_suppl","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1\u20133 prior lines of therapy (LOT): CARTITUDE-2, cohort A","volume":"40","author":"Einsele","year":"2023","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00226","article-title":"Intent matters: real-world applicability of idecabtagene vicleucel usage in the United States","volume":"41","author":"Chakraborty","year":"2023","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e16174","DOI":"10.1111\/ene.16174","article-title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study","volume":"31","author":"Sales","year":"2024","journal-title":"Eur J Neurol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"JCO"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283931","article-title":"Talquetamab in multiple myeloma","volume":"109","author":"Liu","year":"2024","journal-title":"Haematologica."},{"key":"B114","article-title":"BCMA\/GPRC5D\/fcRH5\u2014CARs\/bsAbs\u2014how to choose","volume-title":"SOHO annual meeting","author":"Chari","year":"2023"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","article-title":"and Driscoll JJ(2022), Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction","volume":"10","author":"Rana","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.957157","article-title":"Road testing new CAR design strategies in multiple myeloma","volume":"13","author":"Rana","year":"2022","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102452","article-title":"Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients","volume":"13","author":"Frerichs","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/HS9.0000000000000528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph","year":"2024","journal-title":"Blood Cancer J"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19303","article-title":"Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations","volume":"204","author":"Ravi","year":"2024","journal-title":"Br J Haematol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009681","article-title":"Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy","volume":"7","author":"Charalampous","year":"2023","journal-title":"Blood Adv"},{"key":"B130","doi-asserted-by":"publisher","first-page":"9","DOI":"10.46989\/001c.116261","article-title":"The evolving role of bridging therapy during CAR-T therapy","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9698-5","article-title":"Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors","volume":"36","author":"Driscoll","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235632","article-title":"Targeting proteasomes and the MHC class I antigen presentation machinery to treat cancer, infections and age-related diseases","volume":"15","author":"Rana","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764","article-title":"HDAC6 inhibition releases HR23B to activate proteasomes, expand the tumor immuno-peptidome and amplify T-cell antimyeloma activity","volume":"4","author":"Rana","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0931","article-title":"Mosley A et\u00a0al, Immunoproteasome activation expands the MHC-class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity","volume":"23","author":"Rana","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174249","article-title":"T-cell-based cellular immunotherapy of multiple myeloma: current developments","volume":"14","author":"Simmons","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00228-5","article-title":"Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma","volume":"11","author":"Jagannath","year":"2023","journal-title":"Oncol Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2207742","article-title":"Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China","volume":"26","author":"Wu","year":"2023","journal-title":"J Med Econ"},{"key":"B142","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12885-023-10824-3","article-title":"Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients","volume":"23","author":"Sanoyan","year":"2023","journal-title":"BMC Cancer"},{"key":"B143","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/OTT.S305429","article-title":"Evaluating the therapeutic potential of idecabtagene vicleucel in the treatment of multiple myeloma: evidence to date","volume":"15","author":"Mann","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B144","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-024-01023-9","article-title":"Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study","volume":"14","author":"Gong","year":"2024","journal-title":"Blood Cancer J"},{"key":"B145","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.1200\/JCO.2022.40.16_suppl.8042","article-title":"Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Real-world experience","volume":"40","author":"Hansen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (Ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1182\/blood-2023-190583","article-title":"A real-world comparison of idecabtagene vicleucel and ciltacabtagene autoleucel CAR-T therapy: A single center experience for relapsed\/refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1578529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:20:40Z","timestamp":1750418440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1578529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":150,"alternative-id":["10.3389\/fonc.2025.1578529"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1578529","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1578529"}}